Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma

Summary

This study is a phase Ib, single arm, open label clinical trial that will enroll patients with untreated diffuse large B-cell lymphoma (DLCBL) at moderate or high risk for poor outcome

Timeline

Start

2018-05-21

Primary completion

2021-12-31

Completion

2024-01-16

Publications

• Duque AED, Ferrari PSSM, Ethiraj P, Jaafar C, Qiu Z, Holder K, Butler MJ, Huelgas-Morales G, Karnad A, Dahia PLM, Aguiar RCT. First-Line Combination of R-CHOP with the PDE4 Inhibitor Roflumilast for High-Risk DLBCL. Cancers (Basel). 2024 Nov 18;16(22):3857. doi: 10.3390/cancers16223857.

Drugs

Indications